Oncology (47)

Can an Immunotherapy Combination Improve Outcomes in Patients With Melanoma Metastatic to the Brain?

Approximately 75% of patients with melanoma develop brain metastases before death, which has an extremely poor progonosis (median overall survival, 4-5 mo). The phase 2 CheckMate 204 trial recently published data that showed combining the CTLA4 inhibitor ipilimumab (Yervoy) with the PD-1 inhibitor nivolumab (Opdivo) can arrest or shrink brain...